On 22nd May, the representatives of Huarong Securities Co., Ltd (“Huarong Securities”) including Mr. Minsheng Jian, General Manager of Enterprise Innovation Financing Department, Mr. Yuying Geng, General Manager of Business Division in Zhengzhou visited Beroni China and had a cordial talk with Mr. Jacky Zhang, Executive Chairman of Beroni Group on health industry projects and financial investment and financing.
Mr. Jacky Zhang, Executive Chairman of Beroni Group, and Dr. Zhenghu Jia, Vice President of the Group and President of the International Research Center for Precision Medicine, systematically introduced Beroni Group, including Beroni’s business development strategy, team of scientists, research projects in the field of biotechnology and strategic plans.
Mr. Minsheng Jian and Mr. Yuying Geng provided an overview of the business activities of Huarong Securities, and also gave their suggestions on the development of Beroni Group in the field of portfolio capital management.
Mr. Minsheng Jian stated that each research project of Beroni Group has huge development potential and should be favored by domestic investment institutions. It is inevitable that Beroni Group will develop rapidly and Huarong Securities is pleased to support Beroni Group in the following areas: 1) Assist Beroni Group to sort out the business structure and get the A-share listing in China without affecting its overseas listing (suggesting Beroni Group focuses on the Science and Technology Innovation Board, and treating its pipeline of new drug and medicine projects as the core business); 2) Provide equity investment support using Huarong Securities’ huge investment infrastructure; 3) Provide resources for Beroni Group’s investment and merger activities. “Beroni Group should make use of its own advantages to cooperate with international biopharmaceutical companies to achieve great scientific results, and Beroni Group can also participate as an investor, which is a good way of collaborating.” Mr Jian suggested.
Huarong Securities is a fully licensed securities company approved by the China Securities Regulatory Commission. Huarong Securities provides a comprehensive range of financial services such as asset management, banking, trust, financial leasing, securities brokerage, securities underwriting and sponsorship, financial consulting related to securities trading and securities investment activities, securities investment consulting, securities self-operation, and securities asset management.
The representatives of Huarong Securities highly praised Beroni Group’s international scientific research capability, and commented that Beroni Group has done well in the integration of its international resources and providing its consumers with diversified products and services. With an international scientific research team, Beroni Group’s research projects have strong scientific and technological support and show promising prospects in the healthcare industry. As more and more innovative biotechnology companies emerge in China and become internationalized, international collaboration and innovation are the way forward. China is undergoing a development boom in biotechnology innovation and the recent pandemic have caused rapid industry changes in biotechnology and life sciences which will attract more attention and interest in the capital markets. It is therefore a good opportunity for Beroni Group to develop further in the domestic and international markets under the current global health crisis.
At the end of the visit, the representatives of Huarong Securities expressed great optimism about the development prospect of Beroni Group and expected to have the opportunity to cooperate with Beroni Group to provide a comprehensive financial securities investment and financing services to Beroni Group.
